 New York, New York--Newsfile Corp. - July 6, 2021 - PCG Digital -- A rare form of non-Hodgkins lymphoma, cutaneous T-cell lymphoma CTCL has no current FDA-approved first-line therapies. There are roughly 3,000 new CTCL cases in the United States each year, with more than 20,000 patients living with CTCL.Small cap biotech Soligenix Nasdaq:SNGX is developing and moving toward potential commercialization of HyBryteTM SGX301 or synthetic hypericin as a novel first in class photodynamic therapy... 